62 related articles for article (PubMed ID: 38530313)
1. Is nuchal translucency of 3.0-3.4 mm an indication for cfDNA testing or microarray? - a multicenter retrospective clinical cohort study.
Rybak-Krzyszkowska M; Madetko-Talowska A; Szewczyk K; Bik-Multanowski M; Sakowicz A; Stejskal D; Trková M; Smetanová D; Serafim S; Correia H; Nevado J; Angeles Mori M; Mansilla E; Rutkowska L; Kucińska A; Gach A; Huras H; Kołak M; Srebniak MI
Fetal Diagn Ther; 2024 May; ():. PubMed ID: 38815555
[TBL] [Abstract][Full Text] [Related]
2. Use of a DNA method, QF-PCR, in the prenatal diagnosis of fetal aneuploidies.
Langlois S; Duncan A; ;
J Obstet Gynaecol Can; 2011 Sep; 33(9):955-960. PubMed ID: 21923994
[TBL] [Abstract][Full Text] [Related]
3. Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy.
Brizot ML; Snijders RJ; Butler J; Bersinger NA; Nicolaides KH
Br J Obstet Gynaecol; 1995 Feb; 102(2):127-32. PubMed ID: 7538782
[TBL] [Abstract][Full Text] [Related]
4. Ultrasonographic Fetal Nuchal Translucency Measurements and Cytogenetic Outcomes.
Bellai-Dussault K; Dougan SD; Fell DB; Little J; Meng L; Okun N; Walker MC; Armour CM; Potter BK
JAMA Netw Open; 2024 Mar; 7(3):e243689. PubMed ID: 38530313
[TBL] [Abstract][Full Text] [Related]
5. Prenatal screening for fetal aneuploidy in singleton pregnancies.
Chitayat D; Langlois S; Douglas Wilson R; ;
J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic outcomes following a failed cell-free DNA screen: a population-based retrospective cohort study of 35,146 singleton pregnancies.
Bellai-Dussault K; Meng L; Howley H; Reszel J; Huang T; Lanes A; Walker MC; Okun N; Dougan SD; Armour CM
Am J Obstet Gynecol; 2023 Aug; 229(2):168.e1-168.e8. PubMed ID: 36627072
[TBL] [Abstract][Full Text] [Related]
7. Should cell-free DNA testing be used in pregnancy with increased fetal nuchal translucency?
Miranda J; Paz Y Miño F; Borobio V; Badenas C; Rodriguez-Revenga L; Pauta M; Borrell A
Ultrasound Obstet Gynecol; 2020 May; 55(5):645-651. PubMed ID: 31301176
[TBL] [Abstract][Full Text] [Related]
8. Reexamining the optimal nuchal translucency cutoff for diagnostic testing in the cell-free DNA and microarray era: results from the Victorian Perinatal Record Linkage study.
Hui L; Pynaker C; Bonacquisto L; Lindquist A; Poulton A; Kluckow E; Hutchinson B; Norris F; Pertile MD; Gugasyan L; Kulkarni A; Harraway J; Howden A; McCoy R; da Silva Costa F; Menezes M; Palma-Dias R; Nisbet D; Martin N; Bethune M; Poulakis Z; Halliday J
Am J Obstet Gynecol; 2021 Nov; 225(5):527.e1-527.e12. PubMed ID: 33957116
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of crown-rump length discordance at 11 to 14 weeks in dichorionic twins.
Janssen MK; Levine LD; Bromley B; Chasen ST; Russo ML; Roman AS; Limaye MA; Ranzini AC; Clifford CM; Biggio JR; Subramanian A; Seasely A; Patil AS; Weed S; Page JM; Nicholas S; Idler J; Rao R; Crowder A; Shree R; McLennan G; Dugoff L;
Am J Obstet Gynecol; 2024 Jan; 230(1):83.e1-83.e11. PubMed ID: 37487855
[TBL] [Abstract][Full Text] [Related]
10. Different Cutoff Values for Increased Nuchal Translucency in First-Trimester Screening to Predict Fetal Chromosomal Abnormalities.
Su L; Wu X; Lin N; Xie X; Cai M; Wang M; Zheng L; Xu L
Int J Gen Med; 2021; 14():8437-8443. PubMed ID: 34819751
[TBL] [Abstract][Full Text] [Related]
11. Performance of a universal prenatal screening program incorporating cell-free fetal DNA analysis in Ontario, Canada.
Dougan SD; Okun N; Bellai-Dussault K; Meng L; Howley HE; Huang T; Reszel J; Lanes A; Walker MC; Armour CM
CMAJ; 2021 Aug; 193(30):E1156-E1163. PubMed ID: 34344770
[TBL] [Abstract][Full Text] [Related]
12. Data Resource Profile: Better Outcomes Registry & Network (BORN) Ontario.
Murphy MSQ; Fell DB; Sprague AE; Corsi DJ; Dougan S; Dunn SI; Holmberg V; Huang T; Johnson M; Kotuba M; Bisnaire L; Chakraborty P; Richardson S; Teitelbaum M; Walker MC
Int J Epidemiol; 2021 Nov; 50(5):1416-1417h. PubMed ID: 34097034
[No Abstract] [Full Text] [Related]
13. United States' experience in nuchal translucency measurement: variation according to provider characteristics in over five million ultrasound examinations.
Thornburg LL; Bromley B; Dugoff L; Platt LD; Fuchs KM; Norton ME; McIntosh J; Toland GJ; Cuckle H;
Ultrasound Obstet Gynecol; 2021 Nov; 58(5):732-737. PubMed ID: 33634915
[TBL] [Abstract][Full Text] [Related]
14. Risk of Clinically Significant Chromosomal Microarray Analysis Findings in Fetuses With Nuchal Translucency From 3.0 mm Through 3.4 mm.
Sagi-Dain L; Singer A; Ben Shachar S; Josefsberg Ben Yehoshua S; Feingold-Zadok M; Greenbaum L; Maya I
Obstet Gynecol; 2021 Jan; 137(1):126-131. PubMed ID: 33278279
[TBL] [Abstract][Full Text] [Related]
15. Estimating Risk Ratios and Risk Differences: Alternatives to Odds Ratios.
Holmberg MJ; Andersen LW
JAMA; 2020 Sep; 324(11):1098-1099. PubMed ID: 32930746
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
